David Brancaccio

Now, I mean, the reason we're talking right is the FDA is saying it's going to try to curb some of this further.

It will use, quote, all available compliance and enforcement tools.

What kind of tools do drug regulators have in the U.S.

?

Can Lilly or Novo, the big pharmas, can they meet demand?

But you've worried about standards or lack thereof in this whole area.

What are some of your concerns?

Marta Woszynska is a senior fellow in economic studies at the Brookings Institution Center on Health Policy.

Also just this week, Novo Nordisk announced it's cutting the list price for Ozempic, Wagovi, and the oral diabetes drug Ribelsis by as much as half, but starting the first of next year.

The company's stock is down 40 percent in a month.

Eli Lilly's stock is down just 3 percent during the same period.

The Treasury Department says it will ease restrictions on Venezuelan oil exports to Cuba for, quote, commercial and humanitarian use, dialing down limits that are part of Cuba's worsening energy shortage.

Electricity in Cuba comes from generators running on imported fuel.

In just over a week, a new round of action in the Italian Alps.

The Milan-Cortina Paralympic Games kick off March the 6th.

Dozens of athletes will represent the U.S.

in sled hockey, skiing, wheelchair curling, and snowboarding.

Among the business angles here is the fact that getting to the Paralympics and the Olympics is expensive.

It costs competitors on average $12,000 a year.

And as Marketplace's Kimberly Adams reports, for winter athletes in particular, costs can be even higher.